- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: amfebutamone | BW-323 | Wellbutrin® | Zyban®
bupropion is an approved drug (FDA (1985))
Compound class: Synthetic organic
Comment: The approval status for use of this drug was submitted for re-evaluation by the European Medicines Agency in 2002, following public health concerns around serious adverse reactions associated with its use. These included depression, suicidal thoughts, suicide, seizures, undesirable cardiovascular effects, and angioedema. EU Member States regulatory authorities agreed to keep the product under regular review.
Marketed formulations usually contain bupropion hydrochloride (PubChem CID 62884).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: bupropion
|No information available.|
|Summary of Clinical Use|
|Bupropion is used to aid smoking cessation (in combination with motivational support) in nicotine-dependent patients. Some countries authorise use for additional indications eg major depressive disorder in the US and Canada and seasonal affective disorder in Canada.
In September 2014 the US FDA approved Contrave® (bupropion and naloxone), a fixed-mixture medication, to be used in conjunction with reduced-calorie intake and physical activity, as a treatment for chronic weight management.
|Mechanism Of Action and Pharmacodynamic Effects|
|The mode of action of bupirion in smoking cessation is not completely understood., but appears to involve inhibition of serotonin and dopamine reuptake.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)